GlassScriptPhysician profile
Fallon D Houk
NPI 1417628728
$1,904.56
in general payments reported to CMS, 2019-2025
15 companies · $826 in 2025
The $826 reported for 2025 was more than what 84% of Family providers received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2023: $116 · 2024: $962 · 2025: $826.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,905.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,904.56 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $558.64 | 2024-2025 | |
| Astrazeneca Pharmaceuticals LP | $352.98 | 2024-2025 | Farxiga, Breztri, Airsupra |
| Novo Nordisk INC | $281.16 | 2024-2025 | Ozempic, Rybelsus, Wegovy |
| Sanofi-Aventis U.S. LLC | $245.02 | 2023-2024 | |
| Astellas Pharma US INC | $161.29 | 2024-2025 | Veozah |
| Sumitomo Pharma America, INC. | $74.99 | 2025 | Gemtesa |
| Exact Sciences Corporation | $49.00 | 2024-2025 | Cologuard Collection Kit |
| Medtronic, INC. | $29.90 | 2025 | Intellis Adaptivestim |
| Pfizer INC. | $29.80 | 2025 | |
| Dynavax Technologies Corporation | $25.08 | 2025 | Heplisav-B |
| Boston Scientific Corporation | $24.84 | 2025 | General - Pain Management |
| Organon LLC | $20.72 | 2025 | Nexplanon |
| Glaxosmithkline, LLC. | $20.48 | 2025 | Bexsero, Shingrix, Arexvy |
| Lilly USA, LLC | $15.48 | 2024 | Mounjaro |
| Currax Pharmaceuticals LLC | $15.18 | 2025 | Contrave |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Fallon Houk listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.